Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.
Curr Breast Cancer Rep. 2017 Dec;9(4):236-241
Authors: Schleicher SM, Dickler MN
Purpose of the review: To understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor positive (HR+) breast cancer.
Recent findings: Multiple large trials have investigated this question. The two trials most representative of the dilemma faced in clinical practice are the MA.17R and NSABP-B42 trials, which both investigated the benefit of continuing versus stopping AI therapy beyond 5 years. Both trials showed that extended AI therapy led to a reduction in new or recurrent breast cancers, but had no effect on survival outcomes when death from any cause was included.
Summary: The decision to extend AI therapy beyond 5 years remains a personalized one based on a discussion of the projected risk of recurrence, the expected benefits of prolonged AI treatment, and the patient's ability to tolerate side effects so that quality of life is preserved.
PMID: 29399271 [PubMed]